Therapy with WBM appears to both impact PSA levels and modulate the biology of biochemically recurrent prostate cancer by decreasing immune-suppressive factors, such as myeloid-derived suppressor cells (MDSCs). Here, KLK3 is linked to prostate carcinoma.